Telesis Bio

Telesis Bio Inc., a publicly-traded synthetic biology company headquartered in San Diego, California, provides automated solutions for creating synthetic DNA and mRNA. The company was founded as Codex DNA in 2011 by Dr. Daniel Gibson and J. Craig Venter, with Todd R. Nelson, PhD, also recognized as a founder who led the company as CEO from 2019 until April 2024. In November 2022, the company rebranded from Codex DNA to Telesis Bio to reflect its expanding portfolio into multi-omic and genomics applications. Dr. Gibson, the company's Co-Founder and CTO, is the inventor of the Gibson Assembly® method, a widely used technique in synthetic biology for which his team's work has amassed over 6,000 citations and 300 patents.

Telesis Bio's business model centers on the manufacturing and sale of laboratory instruments, reagents, and related services to a global client base that includes pharmaceutical companies, academic institutions, and contract research organizations. The company generates revenue through the sale of its products and services, reporting a trailing twelve-month revenue of $16.3 million as of June 2024. Its offerings are designed to accelerate research and development in areas like biologics drug discovery, vaccine development, personalized medicine, and cell and gene therapy.

The company's flagship product line is the BioXp® system, an automated benchtop workstation that enables researchers to convert a digital DNA sequence into synthetic genes, clones, variant libraries, and mRNA overnight. This platform consolidates and automates the entire synthesis, cloning, and amplification workflow, significantly reducing turnaround times compared to traditional methods. More recently, Telesis Bio launched the Gibson SOLA™ platform, a next-generation enzymatic DNA synthesis (EDS) technology. SOLA uses a novel enzymatic approach to build DNA in blocks, which results in higher fidelity and faster workflows. This platform integrates with standard lab automation, allowing scientists to maintain control over their intellectual property and timelines by bringing nucleic acid synthesis in-house. The company has secured collaborations and licensing agreements with major industry players like Regeneron and Beckman Coulter Life Sciences to drive the adoption of its technologies.

Keywords: synthetic biology, DNA synthesis, mRNA synthesis, lab automation, gene synthesis, BioXp system, Gibson SOLA, enzymatic DNA synthesis, molecular research, therapeutic discovery, life sciences reagents, automated workstation, biologics discovery, vaccine development, cell therapy, gene therapy, genomics, multi-omics, DNA cloning, Gibson Assembly